News | April 02, 2024
Viatris launches RYZUMVl 0.75% in US
The average time of dilation lasts three to eight hours
The average time of dilation lasts three to eight hours
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
Pfizer to discuss regulatory submission with FDA, potentially leading to eighth indication for ADCETRIS
Acquisition of exclusive commercialization rights for European markets
The U.S. FDA recently approved Xolair as the first and only medicine for children and adults with one or more food allergies
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Keytruda is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
